Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders

Janssen-Cilag AB0 个研究点目标入组 780 人开始时间: 2009年4月15日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1. Written informed consent obtained from patient;
•2. Male or female adult patient >= 18 years old;
•3. Patient diagnosed with schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder demanding long term antipsychotic treatment;
•4. The patient’s psychotic symptoms has, according to clinical judgment, been stable during the past three months without a need for major interventions due to clinical deterioration (like hospitalization and/or major changes in medication);
•5. Patients current main antipsychotic therapy is:
•a. Atypical oral antipsychotic; or
•b. Atypical long acting injectable (LAI) antipsychotic; or
•c. Conventional LAI antipsychotic.
•6. Patient should have been treated with their current main antipsychotic therapy for a minimum of 6 months and a maximum of 24 months.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Patient experiencing an acute relapse/exacerbation of schizophrenia symptoms;
•2. Patient registered on involuntary/compulsory therapy (LPT and forensic patients);
•3. Patient currently participating in a randomized controlled trial.

发起方